We have read with great interest the increasing number of publications reporting that oral contraceptive (OC) 1 formulations can decrease CYP2C19 activity. For example, Palovaara et al. (2003) evaluated the effect of two OC formulations on the hydroxylation of omeprazole. One formulation contained EE (40 g) and LNG (60 g), whereas the second contained LNG (60 g) and was devoid of EE. The combination of EE and LNG increased both the area under the plasma concentration vs. time curve of omeprazole (38%) and the omeprazole to 5-hydroxy omeprazole area under the plasma concentration vs. time curve ratio (48%). LNG alone had no affect on the PK and metabolism of omeprazole. In addition, neither formulation inhibited CYP3A4-catalyzed omeprazole sulfone formation. Because the hydroxylation of omeprazole is widely accepted as an index of CYP2C19 activity (Chang et al., 1995; Lasker et al., 1998; Abelo et al., 2000; Kita et al., 2001) , the authors concluded that OC preparations containing EE decrease CYP2C19 activity. The observations of Palovaara et al. (2003) confirm the findings of Laine et al. (2000) , who also reported an increase (ϳ100%) in the omeprazole to 5-hydroxy omeprazole ratio in plasma. In the same study, the ratio of (S)-mephenytoin to (R)-mephenytoin in urine (S/R ratio) increased from 0.11 to 0.28, and the effect was similar to that observed with subjects genotyped CYP2C19*1/*2 (versus CYP2C19*1/*1). A comparable change in the S/R ratio has been reported by Hagg et al. (2001) and Tamminga et al. (1999) .
trol. Therefore, these data imply that the concentration of inhibitor/K i ratio for EE is very low.
EE has been shown to be a mechanism-based inhibitor (K I , 18 M; k inact , 0.04 min Ϫ1 ) of CYP3A4 in vitro (Lin et al., 2002) . In our hands, up to 70% inhibition of testosterone 6␤-hydroxylase activity was observed when EE (50 M) was preincubated (30 min) with NADPHfortified human liver microsomes. In contrast, preincubation of EE (0.1 to 50 M) with human liver microsomes resulted in no inhibition of (S)-mephenytoin 4Ј-hydroxylase activity. Ticlopidine (10 M), on the other hand, behaved as a preincubation time-dependent inhibitor (50% inhibition) and also served as a positive control (Tateishi et al., 1999; Ko et al., 2000; Ha-Duong et al., 2001) . Based on our preliminary data, therefore, the k inact /K I ratio of EE for CYP2C19 is probably lower than that for CYP3A4 (0.002 min Ϫ1 ⅐ M Ϫ1 ). It is worth noting that despite overt mechanism-based inhibition of CYP3A4 in vitro, EE has a modest effect on the PK and metabolism of midazolam, a sensitive CYP3A4 probe drug (Palovaara et al., 2000; Belle et al., 2002; Lin et al., 2002) . The in vitro study described herein was expanded to include a number of EE metabolites (e.g., EE 3-O-sulfate, EE 3-O-glucuronide, and 2-methoxy EE), and none were shown to be inhibitors of human liver microsomal (S)-mephenytoin 4Ј-hydroxylase activity.
At first glance, it is difficult to conclude that the effect of OCs on CYP2C19 activity is due to inhibition (reversible or mechanismbased) of the enzyme by EE. Further studies are needed to elucidate the mechanism of interaction involving omeprazole and mephenytoin. Toward this end, it will be important to evaluate carefully the estrogenic and progestogenic components of OC formulations and their metabolites, as reversible and mechanism-based inhibitors of CYP2C19 in vitro. In turn, in vitro-in vivo correlations can be attempted. Such studies are important because it has been estimated that up to 70 million women worldwide take OC formulations (Belle et al., 2002) , and relatively little mechanistic information is available concerning the effects of these formulations on cytochromes P450. 
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